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Although Candida albicans remains the
most common opportunistic yeast pathogen in
patients with AIDS and other
immunocompromised persons, species less sus-
ceptible to fluconazole are becoming more
common (1). Recently, a newly described species,
Candida dubliniensis, was isolated from
oropharyngeal lesions in patients with AIDS
living in Dublin, Ireland (2). C. dubliniensis,
phenotypically very similar to C. albicans in
producing both germ tubes and chlamydospores,
has since been recovered from the oral washings
of approximately 25% of 94 HIV-positive Irish
patients with or without AIDS and 3% of 150
HIV-negative Irish persons (3,4), which suggests
that this species belongs to the indigenous
microflora of the oral cavity, albeit in a minority
of healthy persons. Subsequent reports indicate
that the species has a worldwide distribution (4).
The role of C. dubliniensis as a pathogen has
been limited to oral candidiasis. We now report
three cases of candidemia due to C. dubliniensis
in patients not infected with HIV. The yeasts
were initially identified as C. albicans because
each produced germ tubes and chlamydospores;
this identification became suspect when equivocal
carbohydrate assimilation patterns were obtained.
Case 1
Graft-versus-host disease of the skin, liver,
and digestive tract developed in a 39-year-old
woman with chronic myelogenous leukemia
after an allogeneic hematopoietic stem cell
transplant in September 1995, during which she
was treated with cyclosporine and high-dose
prednisolone. Germ tubeproducing Candida
spp., later identified as C. dubliniensis, were
isolated from stool samples obtained for routine
testing. The white-cell count was 2.7 x 109/L
(72% granulocytes); 4 days later fever and ascites
developed, and C. dubliniensis was cultured
from three separate blood cultures (two sets
obtained by venipuncture and one by the central
venous line) taken on the same day (MIC
fluconazole, 0.25 µg/ml). Ascitic fluid obtained by
a sterile puncture also grew C. dubliniensis.
Ascites was probably related to hypoalbuminemia.
An echogram showed no radiologic evidence of
liver candidiasis, although alkaline phosphatase
was elevated (222 U/L; normal < 120 U/L).
Treatment was started intravenously with flucona-
zole, 800 mg/day; 3 days later, C. dubliniensis
were still recovered in one of five blood cultures
taken over 2 days, but from then on, blood
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cultures were yeast-negative. Because the
patient was in stable condition, the central line
was not removed. Cytomegalovirus (CMV)
disease also developed, which could explain the
elevated alkaline phosphatase, with severe
thrombopenia (<20 x 109/L). The patient was
given ganciclovir and hyperimmune gamma-
globulin (Cytotect); Staphylococcus epidermidis
bacteremia also developed, and the patient
died 3 weeks after the onset of candidemia, with
severe graft-versus-host disease stage IV,
complicated by candidemia and CMV disease.
Permission for autopsy was not granted.
Case 2
In July 1995, a 5-year-old boy was treated
with cytotoxic chemotherapy for relapsed
nasopharyngeal rhabdomyosarcoma. Two epi-
sodes of bacteremia caused by Streptococcus
mitis and S. epidermidis followed, and the boy was
treated with ceftazidime and later ciprofloxacin
(combined with vancomycin) for 3 weeks.
Cultures of stools and oral specimens yielded
germ tubeproducing Candida spp. later
identified as C. dubliniensis. Four days before
the onset of candidemia the patient became
febrile;  Staphylococcus aureus and C. dublinien-
sis were cultured from sputum. At this time, the
child was not aplastic (leukocyte count 2 x 109/L).
Flucloxacillin and ceftazidime were started.
When fungal blood cultures were taken, the
patient was very ill, had profuse diarrhea and
high fever, and was leukopenic with a total
leukocyte count of 0.3 x 109/L (granulocytes
<0.1 x 109/L; thrombocytes 12 x 109/L); 1 day
later, three blood cultures, taken over 24 hours
through a central line, yielded C. dubliniensis
(MIC fluconazole, 0.5 µg/ml). Treatment with
12 mg/kg fluconazole was started immediately.
C. dubliniensis were still being recovered from
two blood cultures 2 days after treatment began,
but after that, cultures remained sterile, and the
patient gradually improved. The central line was
removed 20 days after the last positive blood
culture but was not submitted for culture. The
patient was treated with fluconazole for 1 month
(3 weeks intravenously, and 1 week orally) and
was discharged 2 months after the onset of
candidemia. No yeasts were recovered from fecal
cultures and oral washes, but 1 month after
discharge, oral washes again sporadically grew
C. dubliniensis. The patient received further
radiotherapy without any evidence of
candidemia  but died 1 year later of relapsed
rhabdomyosarcoma.
Case 3
An 8-year-old girl with sickle cell disease
combined with ß-thalassemia and recurrent
hemolytic crisis received an allogeneic hemato-
poietic stem cell transplant in January 1995. One
year before, she had a splenectomy because of
hypersplenism. The conditioning regimen for the
transplant consisted of busulfan, cyclophosphamid,
and antithymocyte globulin administered with a
Hickman catheter. Cyclosporine and methotrex-
ate were given as prophylaxis against graft-
versus-host disease. A suspension of cotrimoxazole
and amphotericin B was given as antiinfective
prophylaxis. Seventeen days after transplant,
sepsis syndrome and renal failure developed
while the patient was still profoundly granulocy-
topenic (< 0.1 x 109/L). Germ tubeproducing
Candida spp. later identified as C. dubliniensis
were isolated from two sets of blood cultures
drawn 6 hours apart from a peripheral vein and
from two sets through the central venous
catheter (MIC fluconazole, 0.25 µg/ml). The
patient had no signs of oral candidiasis, and
yeasts were not recovered from cultures (oral
washes and stools). At this time the patient had
already been treated for 72 hours with imipenem
and vancomycin. Because of persistent fever
unresponsive to broad-spectrum antibacterial
agents, intravenous amphotericin B (30 mg) was
empirically added. Once the results of the positive
blood cultures became known, 5-flucytosin
(100  mg/kg) was added to the regimen. After
initiation of amphotericin B, later blood cultures
remained negative for yeasts. The Hickman
catheter was removed 14 days later when the
patient had recovered from neutropenia.
Catheter tip cultures remained negative.
However, low grade fever persisted. Nonetheless,
because the patients condition was stable,
treatment  was changed to oral fluconazole (50 mg
t.i.d.) for another 2 weeks and the patient was
discharged. The cause of persistent fever was not
identified, but approximately 6 months later, the
patient recovered.
Microbiologic Results
All yeast isolates were initially identified
by germ tube and chlamydospore formation as
C. albicans, but carbohydrate assimilation
patterns by commercial test kits (Auxacolor,152 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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Sanofi Pasteur, Paris and API 20C, Analytab
Products Plainview, New York) gave equivocal
results. Furthermore, the isolates did not
elaborate ß-glucosidase, grew very weakly at
42°C, and failed to grow at 45°C (6); they
produced dark green colonies on CHROMagar
Candida plates (Becton Dickinson, Etten-Leur,
The Netherlands) typical of C. dubliniensis (4,5)
and abundant chlamydospores on rice-cream agar
after 24 hours (2). In contrast with C. albicans,
the yeasts isolated from our patients specimens
hybridized poorly with the C. albicansspecific
Ca3 fingerprinting probe (5) and gave character-
istic arbitrary primer phosphatase-polymerase
chain reaction patterns for C. dubliniensis
with primer RP02 (5'-GCGATCCCCA-3'). Each
C. dubliniensis isolate yielded two major bands
at 0.4 kb and 1.0 kb, with up to five weak bands
ranging from 0.9 kb to 1.3 kb. In contrast, with
C. albicans, the two major bands were never
observed. Instead, each C. albicans isolate
yielded approximately 15 bands of various
intensity, ranging from 0.65 kb to 2.4 kb.
Furthermore, banding patterns obtained with
RP02 were clearly different from C. glabrata,
C. krusei, C. tropicalis, and C. parapsilosis. In
vitro susceptibility testing for fluconazole
(powder provided by Pfizer BV, Capelle a/d
IJssel, The Netherlands) was performed by the
broth microdilution method with RPMI-1640
with L-glutamine, buffered with MOPS incu-
bated at 35°C, and read after 48 hours according
to NCCLS M-27A (7). C. parapsilosis ATCC
22019 and C. krusei ATCC 6258 were included as
quality control strains. The isolates from
patients 1 and 2 were deposited as CBS 8500
and CBS 8501 at the yeast division,
Centraalbureau  voor Schimmelcultures (CBS),
Delft, The Netherlands.
C. dubliniensis was first described 3 years
ago (2) and is genetically and phylogenetically
distinct from C. albicans (8). Hitherto, its
pathogenic role has been mainly restricted to
oropharyngeal infections in HIV-infected per-
sons and AIDS patients (3,5). In a recent study of
C. dubliniensis, one isolate recovered from a
blood culture and one from postmortem lung
tissue was examined (6); however, no clinical
data were described to allow determination of the
pathogenic role. The cases we have described
show that C. dubliniensis can cause candidemia
in immunocompromised patients. However,
these may not be the first cases of invasive
disease due to this yeast. Identification and
differentiation from other germ tubeproducing
yeasts on the basis of phenotypic characteristics
has been problematic (8); therefore, the
incidence and prevalence of this organism and its
role in invasive disease have been difficult to
determine. For instance, a strain of C. stellatoidea
originally isolated in 1957 from the sputum of a
patient with bronchopneumonia and deposited
in the British Culture Collection of Pathogenic
Fungi has been shown to be C. dubliniensis (2,3),
and an isolate of C. albicans (from sputum of a
Dutch patient) deposited in the culture collection
of CBS in 1952 has been shown to be
C. dubliniensis (Meis, unpub. obs.). In both
cases, it has not been established whether the
C. dubliniensis isolates were responsible for
invasive infections.
Fluconazole appears to be less active against
C. dubliniensis than against C. albicans (4) since
C. dubliniensis is usually associated with
recurrent episodes of candidiasis and protracted
exposure to azole antifungal drugs in patients
with AIDS. Fluconazole showed excellent in
vitro activity against each of the C. dubliniensis
isolated from the blood cultures of our patients;
each patient responded well clinically.  Never-
theless, it is too early to estimate the true
susceptibility of this species to fluconazole. This
requires the correct identification of the species,
which now seems necessary, given its ability to
cause invasive disease in patients treated for
malignant diseases.
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